ByteDance AI Drug Unit Raises $290 Million
ByteDance has completed a $290 million fundraising round for its newly spun-off AI drugmaking unit, Anew Labs. The Shanghai-headquartered firm achieved a $1.5 billion valuation following its inaugural external investment led by major venture capital firms.
ByteDance has completed a $290 million fundraising round for its newly spun-off AI drug discovery unit, achieving a valuation of $1.5 billion. The inaugural external funding event establishes Anew Labs as a standalone entity independent of its parent company's core operations. ByteDance will retain a 56% stake in the newly formed venture following the transaction.
